CorMedix (NASDAQ:CRMD) vs. MediciNova (NASDAQ:MNOV) Financial AnalysisDefense World · 4 days ago
MediciNova, Inc. (NASDAQ:MNOV) Stock Has Average Target Price of $7.75Defense World · Oct 12, 2026
MediciNova (NASDAQ:MNOV) Stock Price Breaks Above Two Hundred Day Moving Average – Here’s WhyDefense World · Oct 7, 2026
MediciNova to Participate in the Maxim Growth SummitGlobeNewsWire · Oct 6, 2026
Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head ContrastDefense World · Oct 4, 2026
MediciNova Drug Falls Short on Liver Fat Parameter, Stock TumblesBenzinga · Sep 28, 2026MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.06 | -$0.05 | Beat |
| May 15, 2026 | -$0.06 | -$0.05 | Beat |
| Feb 20, 2026 | -$0.10 | -$0.06 | Beat |
| Nov 13, 2025 | -$0.08 | -$0.06 | Beat |
| Aug 14, 2025 | -$0.07 | -$0.07 | Beat |
| May 14, 2025 | -$0.14 | -$0.06 | Beat |